Valuation: Profound Medical Corp.

Market Cap 370M 263M 236M 215M 197M 24.7B 382M 2.6B 1.04B 13.18B 986M 965M 41.61B P/E 2026 *
-8.64x
P/E 2027 * -12.3x
Enterprise Value 370M 263M 236M 215M 197M 24.7B 382M 2.6B 1.04B 13.18B 986M 965M 41.61B EV / Sales 2026 *
10x
EV / Sales 2027 * 6.21x
Free-Float
95.91%
Yield 2026 *
-
Yield 2027 * -
1 day+5.19%
1 week+10.46%
Current month+10.46%
1 month+17.09%
3 months-8.65%
6 months+2.53%
Current year-5.85%
1 week 8.6
Extreme 8.6
10.2
1 month 7.7
Extreme 7.7
10.35
Current year 6.52
Extreme 6.52
12.4
1 year 6.52
Extreme 6.52
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.44
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 59 01/09/2026
Director of Finance/CFO - 14/08/2026
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
17/9/26 Option

Chief Technology Officer

25,000 0.0684%
17/9/26 Option

Chief Executive Officer

100,000 0.2737%
17/9/26 Option

Chief Executive Officer

200,000 0.5475%
Change 5-day change 1-year change 3-year change Capi.($)
+5.19%+10.46%+22.17%-22.60% 263M
+2.63%-0.32%+22.75%+52.69% 257B
-3.36%+4.81%-17.34%+63.31% 157B
+1.73%-0.85%+9.29%+17.76% 162B
-4.23%+1.83%-56.84%-19.05% 61.96B
+1.31%+11.01%+23.90%+52.22% 58.73B
-0.76%+4.13%+0.84%-6.12% 55.42B
-2.05%-2.95%+4.30%+54.85% 49.18B
+1.73%-0.06%+18.49%+62.52% 49.27B
+1.00%-1.11%+23.29%+81.48% 44.96B
Average +0.32%+2.27%+5.08%+33.71% 89.62B
Weighted average by Cap. +0.26%+1.20%+5.29%+41.69%

Financials

2026 *2027 *
Net sales 37.02M 26.26M 23.56M 21.53M 19.65M 2.47B 38.19M 259M 103M 1.32B 98.58M 96.46M 4.16B 59.65M 42.31M 37.95M 34.68M 31.66M 3.98B 61.53M 418M 167M 2.12B 159M 155M 6.7B
Net income -42.96M -30.47M -27.33M -24.98M -22.8M -2.86B -44.31M -301M -120M -1.53B -114M -112M -4.82B -31.42M -22.29M -19.99M -18.27M -16.68M -2.1B -32.41M -220M -87.82M -1.12B -83.67M -81.87M -3.53B
Net Debt - -
Projected Income Statement - Annual - Profound Medical Corp.
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
06/11/26 CA$10.14 +5.19% 48,619
05/11/26 CA$9.640 -2.63% 9,300
04/11/26 CA$9.900 +1.33% 61,323
03/11/26 CA$9.770 +4.16% 11,261
02/11/26 CA$9.380 +2.18% 17,583
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Profound Medical Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.14
Average target price
-

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Profound Medical Corp.